A US biotech company which owns a DNA-testing business in Abingdon is facing a crisis over its plummeting share price.
The US stock exchange Nasdaq has warned Orchid BioSciences that it will be removed from the listing unless its share price rises above the $1 mark before January 8.
Spokesman Tracy Henrikson said: "We hope that this will not happen.
"In any case, 15 per cent of all Nasdaq companies are below $1 and they don't want to de-list all of them.
"We can show what we are doing to improve things and we hope that they will deal with it on a case-by-case basis."
Orchid BioSciences took over Abingdon-based Cellmark Diagnostics two years ago.
In its third quarter, Orchid announced revenues up from $7.4m to $17m, and losses of $22.3m.
Comments: Our rules
We want our comments to be a lively and valuable part of our community - a place where readers can debate and engage with the most important local issues. The ability to comment on our stories is a privilege, not a right, however, and that privilege may be withdrawn if it is abused or misused.
Please report any comments that break our rules.
Read the rules hereComments are closed on this article